Mr James N Ellis, MSW, LCSW | |
101c N Mill St, Saukville, WI 53080-1921 | |
(920) 207-3801 | |
Not Available |
Full Name | Mr James N Ellis |
---|---|
Gender | Male |
Speciality | Social Worker - Clinical |
Location | 101c N Mill St, Saukville, Wisconsin |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1134442023 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | 1993-123 (Wisconsin) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr James N Ellis, MSW, LCSW W6829 County Highway A, Adell, WI 53001-1538 Ph: (920) 207-3801 | Mr James N Ellis, MSW, LCSW 101c N Mill St, Saukville, WI 53080-1921 Ph: (920) 207-3801 |
News Archive
Today, Evolent Health announced that its Complex Care program, which focuses on high-risk chronic patients with extensive care management needs, has been validated by the Care Innovations Validation Institute, an organization that provides health care industry consumers with credible validation of population health outcomes.
Gaining access to the inner workings of a neuron in the living brain offers a wealth of useful information: its patterns of electrical activity, its shape, even a profile of which genes are turned on at a given moment. However, achieving this entry is such a painstaking task that it is considered an art form; it is so difficult to learn that only a small number of labs in the world practice it.
Christoph Rader, PhD, associate professor at the Florida campus of The Scripps Research Institute, has been awarded a $2.875 million, five-year grant from the National Cancer Institute to develop unique antibody-drug conjugates engineered to eradicate one of the most common forms of leukemia, chronic lymphocytic leukemia
Western States Biopharmaceuticals, Inc., a privately-held biotechnology company focusing on the development of novel therapies to treat inflammatory disease, and the University of Colorado announced today that they have entered into a licensing agreement for approaches to inhibiting newly discovered T cell Cytokine Inducing Surface Molecules, or TCISM autoimmune disease drug discovery targets.
› Verified 2 days ago